Patents by Inventor Maximilian von EYNATTEN

Maximilian von EYNATTEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20240091245
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.
    Type: Application
    Filed: November 21, 2023
    Publication date: March 21, 2024
    Inventors: Uli Christian BROEDL, Odd-Erik JOHANSEN, Eric Williams MAYOUX, Nima SOLEYMANLOU, Maximilian von EYNATTEN, Hans-Juergen WOERLE, David Z.I. CHERNEY, Bruce A. PERKINS
  • Pharmaceutical composition, methods for treating and uses thereof
    Patent number: 11918596
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
    Type: Grant
    Filed: July 21, 2021
    Date of Patent: March 5, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uli Christian Broedl, Odd-Erik Johansen, Gabriel Woojai Kim, Eric Williams Mayoux, Afshin Salsali, Nima Soleymanlou, Maximilian von Eynatten, Hans-Juergen Woerle, David Z. I. Cherney, Bruce A. Perkins, Andreas Daiber, Thomas Muenzel
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20240066046
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
    Type: Application
    Filed: October 24, 2023
    Publication date: February 29, 2024
    Inventors: Uli Christian BROEDL, Sreeraj MACHA, Maximilian von EYNATTEN, Hans-Juergen WOERLE
  • CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY
    Publication number: 20240033270
    Abstract: The present invention relates to a certain DPP-4 inhibitor for use in cardio- and/or renoprotective therapy, including in patients at high vascular risk.
    Type: Application
    Filed: October 2, 2023
    Publication date: February 1, 2024
    Inventors: Odd-Erik JOHANSEN, Maximilian VON EYNATTEN, Thomas KLEIN, Hans-Juergen WOERLE
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20230405032
    Abstract: The invention relates to the treatment or prevention of renal impairment and/or complications using a SGLT-2 inhibitor, for example in patients diagnosed with metabolic disorders and related conditions.
    Type: Application
    Filed: September 6, 2023
    Publication date: December 21, 2023
    Inventors: Uli Christian BROEDL, Maximilian von EYNATTEN, Odd-Erik JOHANSEN, Thomas KLEIN, Gerd Roland LUIPPOLD
  • Pharmaceutical composition, methods for treating and uses thereof
    Patent number: 11833166
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: December 5, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uli Christian Broedl, Sreeraj Macha, Maximilian von Eynatten, Hans-Juergen Woerle
  • Medical Use of Pharmaceutical Combination or Composition
    Publication number: 20230381188
    Abstract: The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.
    Type: Application
    Filed: August 7, 2023
    Publication date: November 30, 2023
    Inventors: Thomas MEINICKE, Maximilian VON EYNATTEN
  • Pharmaceutical composition, methods for treating and uses thereof
    Patent number: 11813275
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
    Type: Grant
    Filed: July 21, 2021
    Date of Patent: November 14, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uli Christian Broedl, Odd-Erik Johansen, Gabriel Woojai Kim, Eric Williams Mayoux, Afshin Salsali, Nima Soleymanlou, Maximilian von Eynatten, Hans-Juergen Woerle, David Z.I. Cherney, Bruce A. Perkins, Andreas Daiber, Thomas Muenzel
  • Pharmaceutical composition, methods for treating and uses thereof
    Patent number: 11666590
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: June 6, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uli Christian Broedl, Odd-Erik Johansen, Eric Williams Mayoux, Nima Soleymanlou, Maximilian von Eynatten, Hans-Juergen Woerle, David Z.I. Cherney, Bruce A. Perkins
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20220288012
    Abstract: The present invention relates to methods for treating or preventing chronic kidney disease and cardiovascular disease in patients with chronic kidney disease comprising administering empagliflozin to the patient.
    Type: Application
    Filed: June 3, 2022
    Publication date: September 15, 2022
    Inventors: Maximilian von EYNATTEN, Uli Christian BROEDL, Hans-Juergen WOERLE
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20220226360
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.
    Type: Application
    Filed: April 7, 2022
    Publication date: July 21, 2022
    Inventors: Uli Christian BROEDL, Odd-Erik JOHANSEN, Eric Williams MAYOUX, Nima SOLEYMANLOU, Maximilian von EYNATTEN, Hans-Juergen WOERLE, David Z.I. CHERNEY, Bruce A. PERKINS
  • Cardio- and Renosafe Antidiabetic Therapy
    Publication number: 20220160717
    Abstract: The present invention relates to cardio- and renosafe antidiabetic therapy.
    Type: Application
    Filed: February 8, 2022
    Publication date: May 26, 2022
    Inventors: Maximilian VON EYNATTEN, Odd-Erik JOHANSEN
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20220110961
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
    Type: Application
    Filed: July 21, 2021
    Publication date: April 14, 2022
    Inventors: Uli Christian BROEDL, Odd-Erik JOHANSEN, Gabriel Woojai KIM, Eric Williams MAYOUX, Afshin SALSALI, Nima SOLEYMANLOU, Maximilian von EYNATTEN, Hans-Juergen WOERLE, David Z.I. CHERNEY, Bruce A. PERKINS, Andreas DAIBER, Thomas MUENZEL
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20220096505
    Abstract: The invention relates to the treatment or prevention of renal impairment and/or complications using a SGLT-2 inhibitor, for example in patients diagnosed with metabolic disorders and related conditions.
    Type: Application
    Filed: June 14, 2021
    Publication date: March 31, 2022
    Inventors: Uli Christian BROEDL, Maximilian von EYNATTEN, Odd-Erik JOHANSEN, Thomas KLEIN, Gerd Roland LUIPPOLD
  • USE OF A DPP-4 INHIBITOR IN PODOCYTES RELATED DISORDERS AND/OR NEPHROTIC SYNDROME
    Publication number: 20210379073
    Abstract: The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome.
    Type: Application
    Filed: August 19, 2021
    Publication date: December 9, 2021
    Inventors: Thomas KLEIN, Maximilian von EYNATTEN, Michael MARK
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20210346418
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
    Type: Application
    Filed: July 21, 2021
    Publication date: November 11, 2021
    Inventors: Uli Christian BROEDL, Odd-Erik JOHANSEN, Gabriel Woojai KIM, Eric Williams MAYOUX, Afshin SALSALI, Nima SOLEYMANLOU, Maximilian von EYNATTEN, Hans-Juergen WOERLE, David Z. I. CHERNEY, Bruce A. PERKINS, Andreas DAIBER, Thomas MUENZEL
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20210299153
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
    Type: Application
    Filed: June 10, 2021
    Publication date: September 30, 2021
    Inventors: Uli Christian BROEDL, Sreeraj MACHA, Maximilian von EYNATTEN, Hans-Juergen WOERLE
  • METHODS FOR TREATING, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
    Publication number: 20210275558
    Abstract: The present invention relates to methods, pharmaceutical compositions and uses thereof for treating and alleviating Alport syndrome, various aspects and symptoms associated with Alport syndrome in a patient in need thereof comprising administering empagliflozin to the patient.
    Type: Application
    Filed: July 23, 2019
    Publication date: September 9, 2021
    Applicants: Boehringer Ingelheim International GmbH, GEORG-AUGUST UNIVERSITAET GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS, UNIVERSITAETSMEDIZIN
    Inventors: Maximilian Von Eynatten, Oliver Gross, Sibylle Jenny Hauske
  • Pharmaceutical composition, methods for treating and uses thereof
    Patent number: 11090323
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: August 17, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uli Christian Broedl, Sreeraj Macha, Maximilian von Eynatten, Hans-Juergen Woerle
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20210228533
    Abstract: The present invention relates to methods for treating or preventing chronic kidney disease and cardiovascular disease in patients with chronic kidney disease comprising administering empagliflozin to the patient.
    Type: Application
    Filed: November 10, 2020
    Publication date: July 29, 2021
    Inventors: Maximilian von EYNATTEN, Uli Christian BROEDL, Hans-Juergen WOERLE